{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=8",
    "query": {
      "condition": "Relapsed, Refractory Malignant Neoplasms",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 3443,
    "total_pages": 345,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2C+Refractory+Malignant+Neoplasms&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T07:53:30.234Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02119468",
      "title": "Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Plasma Cell Myeloma",
        "Recurrent Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "ixazomib citrate",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2014-06-30",
      "completion_date": "2022-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02119468"
    },
    {
      "nct_id": "NCT02042950",
      "title": "A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-07-14",
      "completion_date": "2017-12-20",
      "has_results": true,
      "last_update_posted_date": "2019-05-01",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02042950"
    },
    {
      "nct_id": "NCT06680752",
      "title": "Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia, in Relapse",
        "Acute Myeloid Leukemia Refractory",
        "MDS (Myelodysplastic Syndrome)"
      ],
      "interventions": [
        {
          "name": "ARD103",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ARCE Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2025-05-20",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 3,
      "location_summary": "Charlotte, North Carolina • Winston-Salem, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06680752"
    },
    {
      "nct_id": "NCT02043847",
      "title": "TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma, Relapsed",
        "Multiple Myeloma, Refractory to Standard Treatment"
      ],
      "interventions": [
        {
          "name": "Total Marrow Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Autologous transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-01-14",
      "completion_date": "2016-09-14",
      "has_results": true,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02043847"
    },
    {
      "nct_id": "NCT01329289",
      "title": "SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma in Relapse",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "SOM230",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-12",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2016-02-12",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01329289"
    },
    {
      "nct_id": "NCT00002908",
      "title": "Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "bryostatin 1",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1996-12",
      "completion_date": "2001-11",
      "has_results": false,
      "last_update_posted_date": "2013-04-05",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002908"
    },
    {
      "nct_id": "NCT06994676",
      "title": "A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High-risk Myelodysplastic Syndrome",
        "Chronic Myelomonocytic Leukemia (CMML)",
        "AML - Acute Myeloid Leukemia",
        "Chronic Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "CBX-250",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crossbow Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2025-07-16",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Palo Alto, California • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06994676"
    },
    {
      "nct_id": "NCT03179917",
      "title": "Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Involved Site Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-06-08",
      "completion_date": "2027-06",
      "has_results": true,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 9,
      "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03179917"
    },
    {
      "nct_id": "NCT03379493",
      "title": "Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphomas Non-Hodgkin's B-Cell"
      ],
      "interventions": [
        {
          "name": "ET190L1 ARTEMIS™ T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Eureka Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-04-04",
      "completion_date": "2019-01-30",
      "has_results": false,
      "last_update_posted_date": "2019-02-04",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03379493"
    },
    {
      "nct_id": "NCT02200757",
      "title": "Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Aldoxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2015-04-20",
      "completion_date": "2017-05-15",
      "has_results": true,
      "last_update_posted_date": "2024-06-25",
      "last_synced_at": "2026-10-08T07:53:30.234Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Pasadena, California • Fleming Island, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Fleming Island",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02200757"
    }
  ]
}